Cargando…

Potential SARS-CoV-2 vaccines: Concept, progress, and challenges

Since September 2020, the world has had more than 28 million cases of coronavirus disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 outbreak. A pressing need is evident for the development of a potent vaccine to control the SARS-CoV-2. Institutions and companies in man...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosseini, Seyede Atefe, Zahedipour, Fatemeh, Mirzaei, Hamed, Kazemi Oskuee, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006194/
https://www.ncbi.nlm.nih.gov/pubmed/33895475
http://dx.doi.org/10.1016/j.intimp.2021.107622
_version_ 1783672264899690496
author Hosseini, Seyede Atefe
Zahedipour, Fatemeh
Mirzaei, Hamed
Kazemi Oskuee, Reza
author_facet Hosseini, Seyede Atefe
Zahedipour, Fatemeh
Mirzaei, Hamed
Kazemi Oskuee, Reza
author_sort Hosseini, Seyede Atefe
collection PubMed
description Since September 2020, the world has had more than 28 million cases of coronavirus disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 outbreak. A pressing need is evident for the development of a potent vaccine to control the SARS-CoV-2. Institutions and companies in many countries have announced their vaccine research programs and progress against the COVID-19. While most vaccines go through the designation and preparation stages, some of them are under evaluation for efficacy among animal models and clinical trials, and three approved vaccine candidates have been introduced for limited exploitation in Russia and China. An effective vaccine must induce a protective response of both cell-mediated and humoral immunity and should meet the safety and efficacy criteria. Although the emergence of new technologies has accelerated the development of vaccines, there are several challenges on the way, such as limited knowledge about the pathophysiology of the virus, inducing humoral or cellular immunity, immune enhancement with animal coronavirus vaccines, and lack of an appropriate animal model. In this review, we firstly discuss the immune responses against SARS-CoV-2 disease, subsequently, give an overview of several vaccine platforms for SARS-CoV-2 under clinical trials and challenges in vaccine development against this virus.
format Online
Article
Text
id pubmed-8006194
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-80061942021-03-29 Potential SARS-CoV-2 vaccines: Concept, progress, and challenges Hosseini, Seyede Atefe Zahedipour, Fatemeh Mirzaei, Hamed Kazemi Oskuee, Reza Int Immunopharmacol Review Since September 2020, the world has had more than 28 million cases of coronavirus disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 outbreak. A pressing need is evident for the development of a potent vaccine to control the SARS-CoV-2. Institutions and companies in many countries have announced their vaccine research programs and progress against the COVID-19. While most vaccines go through the designation and preparation stages, some of them are under evaluation for efficacy among animal models and clinical trials, and three approved vaccine candidates have been introduced for limited exploitation in Russia and China. An effective vaccine must induce a protective response of both cell-mediated and humoral immunity and should meet the safety and efficacy criteria. Although the emergence of new technologies has accelerated the development of vaccines, there are several challenges on the way, such as limited knowledge about the pathophysiology of the virus, inducing humoral or cellular immunity, immune enhancement with animal coronavirus vaccines, and lack of an appropriate animal model. In this review, we firstly discuss the immune responses against SARS-CoV-2 disease, subsequently, give an overview of several vaccine platforms for SARS-CoV-2 under clinical trials and challenges in vaccine development against this virus. Elsevier B.V. 2021-08 2021-03-29 /pmc/articles/PMC8006194/ /pubmed/33895475 http://dx.doi.org/10.1016/j.intimp.2021.107622 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Hosseini, Seyede Atefe
Zahedipour, Fatemeh
Mirzaei, Hamed
Kazemi Oskuee, Reza
Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
title Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
title_full Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
title_fullStr Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
title_full_unstemmed Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
title_short Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
title_sort potential sars-cov-2 vaccines: concept, progress, and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006194/
https://www.ncbi.nlm.nih.gov/pubmed/33895475
http://dx.doi.org/10.1016/j.intimp.2021.107622
work_keys_str_mv AT hosseiniseyedeatefe potentialsarscov2vaccinesconceptprogressandchallenges
AT zahedipourfatemeh potentialsarscov2vaccinesconceptprogressandchallenges
AT mirzaeihamed potentialsarscov2vaccinesconceptprogressandchallenges
AT kazemioskueereza potentialsarscov2vaccinesconceptprogressandchallenges